Loading
A phase 1 trial of GKL-006 Injection run by Beijing Gene Key Life Technology Co., Ltd, active and no longer recruiting.
A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma is a phase 1 interventional study registered as NCT07713290 by Beijing Gene Key Life Technology Co., Ltd, with 6 participants planned, started 2025-04-03. Conditions recorded: Hepatocellular Carcinoma (HCC) and Unresectable Hepatocellular Cancer. Interventions recorded: GKL-006 Injection and Transarterial chemoembolization (TACE).
Shares Beijing Gene Key Life Technology, GKL-006 Injection, Hepatocellular carcinoma and the tag pipeline.
Shares Beijing Gene Key Life Technology, GKL-006 Injection, Hepatocellular carcinoma and the tag pipeline.
Shares Beijing Gene Key Life Technology, GKL-006 Injection and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Shares Hepatocellular carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/